Steve Rees
About
Steve Rees is from United Kingdom. Steve is currently Senior Vice President at AstraZeneca, located in Cambridge, England, United Kingdom. Steve also works as Elected Trustee (Industry) at British Pharmacological Society, a job Steve has held since Jan 2020. In Steve's previous role as a Vice President Discovery Biology at AstraZeneca, Steve worked in Cambridge, United Kingdom until Jul 2023. Prior to joining AstraZeneca, Steve was a Chairman of the European laboratory Research and Innovation Group (ELRIG) at ELRIG UK and held the position of Chairman of the European laboratory Research and Innovation Group (ELRIG) at Cambridge, United Kingdom. Prior to that, Steve was a Member of Board of Directors at ELRIG from Nov 2013 to Jul 2023. Steve started working as Chair Europe Council at Society for Laboratory Automation and Screening in Nov 2013. From May 2011 to Jul 2023, Steve was Vice-President, Screening Sciences and Sample Management at AstraZeneca. Prior to that, Steve was a Section President at Society for Laboratory Automation and Screening from Jan 2011 to Jul 2023. Steve started working as Director, Screening and CompoundProfiling at GSK in Jan 2005.
You can find Steve Rees's email address at finalscout.com. FinalScout is a free professional database with over five hundred million business professional profiles and over two hundred million company profiles.
Steve Rees's current jobs
Member of the BPS council
Steve Rees's past jobs
Leader of Discovery Biology at AstraZeneca; a global research department accoutable for reagent generation, assay development, chemical biology, target identification and target validation capabilities
Memberof the Board of Directors of the European laboratory Robiotics Interest Group
Chair of the Europe Council of SLAS ccountable for delivering a strategic vision and business plan for the growthof SLAS in Europe
Vice-preseident for Global accountability for the development and application of the AstraZeneca Human Biological Sample and small molecule Compound Collection. Additional accountability for hit discovery and compound profiling acoss AstraZeneca sites in UK, Sweden and US.